Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OncoCyte

OncoCyte
2009 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
OCX STOCK SYMBOL
3 INVESTMENTS
$3.02 SHARE PRICE (As of Friday Closing)
Description

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, the company also developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through United States and it earns revenue from the sale of diagnostic tests.

Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Primary Industry
Diagnostic Equipment
Other Industries
Discovery Tools (Healthcare)
Stock Exchange
ASE
Primary Office
  • 1010 Atlantic Avenue
  • Suite 102
  • Alameda, CA 94501
  • United States

+1 (510) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoCyte’s full profile, request a free trial.

OncoCyte Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.50 - $6.92 $172M $2.98 -$0.40 277K 60.6M

OncoCyte Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 73,913 46,500 136,710 187,694
Revenue 0 0 0
EBITDA (18,805) (14,979) (18,578) (10,753)
Net Income (18,971) (15,754) (19,375) (11,168)
Total Assets 32,770 9,518 10,216 14,447
Total Debt 1,222 1,719 2,497 512
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OncoCyte Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore OncoCyte‘s full profile, request access.

Request full access to PitchBook

OncoCyte Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nucleix Venture Capital-Backed Rehovot, Israel 00 000.00 0000000000 000.00
00000000000 000000 Venture Capital-Backed Birmingham, AL 00 00.000 0000000000 0 00.000
0000000000 Venture Capital-Backed Pittsburgh, PA 0 00.00 00000000000 00.00
000000 00000000000 Venture Capital-Backed Pleasanton, CA 000000&0
00000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

OncoCyte Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000000 10-Jan-2020 000000000000000000 0000 Biotechnology 000000 000000 00
00000 00000000 05-Sep-2019 000000000000000000 0000 Diagnostic Equipment
Cell Targeting 28-Jan-2011 Merger/Acquisition 00.00 Biotechnology
To view this company’s complete investment and acquisition history, request access »

OncoCyte Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore OncoCyte‘s full profile, request access.

Request full access to PitchBook

OncoCyte Executive Team (7)

Name Title Board
Seat
Contact
Info
Ronald Andrews Chief Executive Officer & Board Member
William Annett Chief Executive Officer & Board Member
Mitchell Levine Chief Financial Officer
Albert Parker JD Chief Operating Officer
Lyndal Hesterberg Ph.D Chief Scientific Officer & Senior Vice President

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

OncoCyte Board Members (9)

Name Representing Role Since Contact
Info
Adi Mohanty Lineage Cell Therapeutics Board Member 000 0000
Alfred Kingsley JD Self Board Member 000 0000
Andrew Last Ph.D Self Board Member 000 0000
Andy Arno OncoCyte Board Member 000 0000
Cavan Redmond OncoCyte Chairman & Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »